Login / Signup

Direct oral anticoagulants for the treatment of Mondor's disease not responding to low-molecular weight heparin.

Alessandra SerraoBenedetta LucaniErminia BaldacciLuciano FioriAntonio Chistolini
Published in: Phlebology (2020)
Mondor's disease is a rare condition and usually treated with low-molecular weight heparin and non-steroidal anti-inflammatory drugs. Because of paucity of cases and for the usually spontaneous resolution, there is not a standard treatment strategy and the use of oral anticoagulation in controversial. We reported the efficacy of direct oral anticoagulants in the recurrent Mondor's disease refractory to standard therapy.
Keyphrases
  • direct oral anticoagulants
  • venous thromboembolism
  • atrial fibrillation
  • anti inflammatory drugs
  • stem cells
  • growth factor
  • combination therapy
  • mesenchymal stem cells
  • single molecule
  • replacement therapy